Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst
09:00am, Sunday, 29'th Dec 2024
Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets c
Novo Nordisk Is Ready to Ramp Up GLP-1 Manufacturing Following $11B Factory Deal
04:21pm, Thursday, 19'th Dec 2024
Novo has handed Wolff one of the most complex jobs in all of pharmaceuticals.
Viking Therapeutics: Holiday Gift
10:30am, Thursday, 19'th Dec 2024
Viking Therapeutics has seen a significant drop, losing 50% in value since late October, despite positive news and promising GLP-1 drug developments. The biotech's oral GLP-1 candidate VK2735 showed i
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
09:15am, Thursday, 19'th Dec 2024
BALTIMORE--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapie
Lexaria's Registered GLP-1 Study #4 Begins Dosing
09:05am, Thursday, 19'th Dec 2024
Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "C
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
08:30am, Thursday, 19'th Dec 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, to
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
10:38am, Wednesday, 18'th Dec 2024
Recent sales of a little-known stock, Madrigal Pharmaceuticals NASDAQ: MDGL, could bode well for Novo Nordisk A/S NYSE: NVO. The pharma industry giant has seen explosive sales growth for its GLP-1 ago
BEIJING and BRIDGEWATER, N.J. , Dec. 18, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087.SH), is pleased to announce that the Food and Drug Administration (
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
08:50am, Monday, 16'th Dec 2024
Successful Completion of All Planned Implants in GLP Study enVVe Delivery System Demonstrates Consistent Performance Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP
Conagra Brands Introduces Badges on Select Healthy Choice Products, Leading Consumers to GLP-1-Friendly Options
10:28am, Thursday, 12'th Dec 2024
CHICAGO , Dec. 12, 2024 /PRNewswire/ -- With the rising popularity of GLP-1 medications among Americans for diabetes and weight management, Conagra Brands is proud to announce a first-of-its-kind init
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
09:10am, Monday, 09'th Dec 2024
Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide KELOWNA, BC / ACCESSWIRE / December 9, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)
BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root caus
Structure CEO on the competitive landscape for oral GLP-1 drugs
06:17pm, Thursday, 05'th Dec 2024
Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the design of its pivotal Phase 3 LUCIDITY clinical trial f
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?
08:27am, Tuesday, 03'rd Dec 2024
There's a growing number of companies entering the weight loss space, focusing on GLP-1 drugs which can be game changers for their businesses. And one of them is Viking Therapeutics (VKTX -2.70%), whi
